Description: GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel.
Home Page: www.gsk.com
GSK Technical Analysis
980 Great West Road
Brentford,
TW8 9GS
United Kingdom
Phone:
44 20 8047 5000
Officers
| Name | Title |
|---|---|
| Ms. Emma Natasha Walmsley | CEO & Director |
| Mr. Iain James Mackay | CFO & Exec. Director |
| Ms. Julie Brown | Chief Financial Officer |
| Ms. Shobie Ramakrishnan | Chief Digital & Technology Officer |
| Mr. Tony Wood | Chief Scientific Officer |
| Ms. Sarah Elton-Farr | Head of Investor Relations |
| Mr. James Ford | Sr. VP & Group Gen. Counsel of Legal & Compliance |
| Ms. Sally Jackson | Sr. VP of Global Communications & CEO Office |
| Ms. Diana Conrad | Chief People Officer |
| Mr. David Simon Redfern | Chief Strategy Officer |
Exchange: LSE
Country: UK : United Kingdom
Currency: Pence sterling (p)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 9.6712 |
|---|---|
| Trailing PE: | 12.9339 |
| Price-to-Book MRQ: | 6.4589 |
| Price-to-Sales TTM: | 1.5768 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 90096 |